Cargando…
Erythropoietin inhibits osteoblast function in myelodysplastic syndromes via the canonical Wnt pathway
The effects of erythropoietin on osteoblasts and bone formation are controversial. Since patients with myelodysplastic syndromes often display excessively high erythropoietin levels, we aimed to analyze the effect of erythropoietin on osteoblast function in myelodysplastic syndromes and define the r...
Autores principales: | Balaian, Ekaterina, Wobus, Manja, Weidner, Heike, Baschant, Ulrike, Stiehler, Maik, Ehninger, Gerhard, Bornhäuser, Martin, Hofbauer, Lorenz C, Rauner, Martina, Platzbecker, Uwe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ferrata Storti Foundation
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777191/ https://www.ncbi.nlm.nih.gov/pubmed/29079596 http://dx.doi.org/10.3324/haematol.2017.172726 |
Ejemplares similares
-
Luspatercept mitigates bone loss driven by myelodysplastic neoplasms and estrogen-deficiency in mice
por: Weidner, Heike, et al.
Publicado: (2022) -
Machine learning assisted real-time deformability cytometry of CD34+ cells allows to identify patients with myelodysplastic syndromes
por: Herbig, Maik, et al.
Publicado: (2022) -
Myelodysplastic Syndromes and Metabolism
por: Balaian, Ekaterina, et al.
Publicado: (2021) -
Glucocorticoids suppress Wnt16 expression in osteoblasts in vitro and in vivo
por: Hildebrandt, Susanne, et al.
Publicado: (2018) -
Author Correction: Glucocorticoids suppress Wnt16 expression in osteoblasts in vitro and in vivo
por: Hildebrandt, Susanne, et al.
Publicado: (2020)